Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib
malate before surgery may make the tumor smaller and reduce the amount of normal tissue that
needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that
remain after surgery.
PURPOSE: This phase II trial is studying how well giving sunitinib malate before and after
surgery works in treating patients with metastatic kidney cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Barts and the London School of Medicine and Dentistry